News

The deal, facilitated by the Johnson & Johnson Innovation Center, will see Janssen develop and may commercialize the pharmaceutical candidate in inflammatory bowel disease (IBD). As part of

As part of the deal, the research capabilities of the two parties will be brought together to identify new immune-modulatory agents for oncology, autoimmune and respiratory disorders. In

The deal will see evaluation of the safety, tolerability and efficacy of Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with Lilly compounds in multiple clinical trials. As part

Enadenotucirev (previously called as ColoAd1) is currently being evaluated in a Phase I/II trial (OCTAVE) in platinum-resistant ovarian cancer patients across multiple UK cancer centres. The Phase I/II

The move follows a deal signed in April 2014, under which Novartis had agreed with GSK to create a global consumer healthcare JV as part of its global

Beta-lactamase inhibitors are designed to restore or potentiate the activity of beta-lactam antibiotics. As part of the deal, Roche secured worldwide rights from both companies to develop and

Under the deal, Colchicine Tablets, USP will be the only colchicine product on the market that is therapeutically equivalent and automatically substitutable for prescriptions written for Colcrys Tablets.

As part of the deal, Mundipharma and Purdue could make payments in excess of $1bn to Esteve if all development, regulatory and sales milestones are met across the

Elite One, a holding company majority-owned by Ampersand Capital Partners, a middle-market growth equity firm with a track record of success operating and growing leading manufacturing businesses in